Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...

The DNA testing company would sell for a fraction of its peak valuation of $6 billion to a biotech aiming to use its data ...

Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based drugmaker is set to take over 23andMe after winning a bankruptcy ...

Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as ...

The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.

Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.

It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...

I’ll admit to being surprised initially by the mid-month announcement that Regeneron Pharmaceuticals planned to buy out of ...